Cognitive Function
Conditions
Brief summary
A randomized, double-blind, placebo-controlled direct-to-consumer study of health and wellness products on cognitive function and related health outcomes
Detailed description
This is a randomized, double-blind, placebo-controlled study conducted with adult participants, residing in the United States. Eligible participants will (1) endorse a desire for better concentration, (2) have the opportunity for meaningful improvement (at least 20%) in their primary health outcome, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study. Participants that report a known cardiac dysfunction, liver or kidney disease may be excluded. Participants that report a known contraindication or with well-established, significant safety concerns due to illness will be excluded. Heavy drinkers and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Participants that report taking medications with a known contraindication or with well-established, significant safety concerns will be excluded. Self-reported data are collected electronically from eligible participants for 7 weeks. Participant reports of health indicators will be collected at baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic, there are no in-person visits or assessments for this real-world evidence study.
Interventions
DIETARY_SUPPLEMENTPlacebo Control Form 1
Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTClarity Active Study Product 1.1 Usage
Participants will use their Radicle Clarity Active Study Product 1.1 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTPlacebo Control Form 2
Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTClarity Active Study Product 2.1 Usage
Participants will use their Radicle Clarity Active Study Product 2.1 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTPlacebo Control Form 3
Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTClarity Active Study Product 3.1 Usage
Participants will use their Radicle Clarity Active Study Product 3.1 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTClarity Active Study Product 3.2 Usage
Participants will use their Radicle Clarity Active Study Product 3.2 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTPlacebo Control Form 4
Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTClarity Active Study Product 4.1 Usage
Participants will use their Radicle Clarity Active Study Product 4.1 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTPlacebo Control Form 5
Participants will use their Placebo Control Form 5 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTClarity Active Study Product 5.1 Usage
Participants will use their Radicle Clarity Active Study Product 5.1 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTClarity Active Study Product 5.2 Usage
Participants will use their Radicle Clarity Active Study Product 5.2 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTPlacebo Control Form 6
Participants will use their Placebo Control Form 6 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTClarity Active Study Product 6.1 Usage
Participants will use their Radicle Clarity Active Study Product 6.1 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTPlacebo Control 6.1.0
Participants will use their Placebo Control 6.1.0 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTClarity Active Study Product 6.1.1 Usage
Participants will use their Radicle Clarity Active Study Product 6.1.1 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTClarity Active Study Product 6.1.2 Usage
Participants will use their Radicle Clarity Active Study Product 6.1.2 as directed for a period of 6 weeks.
Sponsors
Radicle Science
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Masking description
The investigator is blinded to the participants' assigned study products. Participants are blinded to the study product they received.
Intervention model description
Participants will be stratified based on their gender assigned at birth and health outcome score during enrollment, then randomized to one of the study arms. Each participant will have an equal chance of being assigned to any study arm.
Eligibility
Sex/Gender
ALL
Age
21 Years to 105 Years
Healthy volunteers
Yes
Inclusion criteria
* Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities. Assigned sex at birth will determine sex-specific recruitment and surveys (male vs female) employed, when needed * Resides in the United States * Endorses better concentration or cognitive function (fewer feelings of brain fog) as a primary desire * Has the opportunity for at least 20% improvement in their primary health outcome * Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study
Exclusion criteria
* Report being pregnant, trying to become pregnant, or breastfeeding * Unable to provide a valid US shipping address and mobile phone number * Reports current enrollment in another clinical trial * Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day) * Unable to read and understand English * Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety lak * Reports a diagnosis or cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients. NYHA (New York Heart Association) Class Ill or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure * Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients. Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOls (monoamine oxidase inhibitors), or thyroid products * Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s) * Lack of reliable daily access to the internet
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in cognitive function | 6 weeks | Mean difference in cognition function score as assessed by Patient Reported Outcome Measurement System (PROMIS) Cognitive Function Short Form 8A (scale 8-40; where the higher scores correspond to greater cognitive function) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in fatigue | 6 weeks | Mean difference in fatigue score as assessed by PROMIS Fatigue 4A (scale 4-20; where higher scores correspond to more severe fatigue) |
| Change in sleep-related impairment | 6 weeks | Mean difference in sleep-related impairment score as assessed by PROMIS Sleep-Related Impairment 4A (scale 4-20; with higher scores corresponding to greater sleep-related impairment) |
| Minimal clinical importance difference (MCID) in cognitive function | 6 weeks | Likelihood of achieving a MCID in cognitive function, as measured by PROMIS Cognitive Function Short Form 8A (scale 8-40; where the higher scores correspond to greater cognitive function) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change in mood (emotional distress-depression) | 6 weeks | Mean difference in mood score as assessed by PROMIS Depression 4A (scale 4-20; where higher scores correspond to more severe depression) |
| Change in concentration of at-home (direct-to-consumer) specimen assays either saliva, blood or stool | 6 weeks | Mean difference in specimen assays as surrogates and/or markers for health outcomes. (Optional; among consented participants only) Potentially include saliva (IgG, cytokines, DHEA-S, Estradiol, Progesterone, Testosterone, Cortisol, Melatonin, CRP) blood (1 drop) (Cortisol, Homocysteine, Ferritin, TSH, HbA1c, Insulin, Vitamin D, DHEA-S, Testosterone, Estradiol, FSH, Total Cholesterol, HDL, LDL, Triglycerides, ApoA1, ApoB). Stool (microbial diversity). |
Countries
United States
Outcome results
None listed